Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Assets Related To RHOFADE® (Oxymetazoline Hydrochloride) Cream 1% from EPI Health, LLC for $8 million on August 31, 2023. Transaction is subject to Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. and Morris, Nichols, Arsht & Tunnell LLP served as legal advisors to EPI Health, LLC and K&L Gates LLP served as legal advisor to Mayne Pharma Group Limited (ASX:MYX).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.93 AUD | -2.39% | +4.05% | +12.68% |
Feb. 26 | Mayne Pharma Group Swings to Loss in Fiscal H1 Despite Revenue Growth; Shares Jump 15% | MT |
Feb. 25 | Transcript : Mayne Pharma Group Limited, H1 2024 Earnings Call, Feb 26, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.68% | 367M | |
+19.62% | 43.34B | |
+20.44% | 21.96B | |
+10.86% | 14.09B | |
+13.07% | 13.64B | |
+37.46% | 11.43B | |
-8.59% | 6.86B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+8.46% | 5.22B |
- Stock Market
- Equities
- MYX Stock
- News Mayne Pharma Group Limited
- Mayne Pharma Group Limited agreed to acquire Assets Related To RHOFADE® (Oxymetazoline Hydrochloride) Cream 1% from EPI Health, LLC for $8 million.